4:[["$","header",null,{"className":"app-header","children":["$","div",null,{"className":"container","children":["$","div",null,{"className":"row","children":["$","nav",null,{"className":"navbar navbar-expand-sm navbar-dark","children":[["$","a",null,{"className":"navbar-brand","href":"/","children":[["$","img",null,{"src":"/images/pem-logo-sm.png","alt":"Private Equity Markets","className":"lazy"}],"Private Equity Markets"]}],["$","ul",null,{"className":"navbar-nav ml-auto","children":[["$","li",null,{"className":"nav-item","children":["$","a",null,{"className":"nav-link","href":"/about","children":"About Us"}]}],["$","li",null,{"className":"nav-item","children":["$","a",null,{"className":"nav-link","href":"/companies/gold","children":"Mining Companies"}]}],["$","li",null,{"className":"nav-item","children":["$","a",null,{"className":"nav-link","href":"/companies/public?hot=true","children":"Public Companies"}]}],["$","li",null,{"className":"nav-item","children":["$","a",null,{"className":"nav-link","href":"/companies/cannabis","children":"Cannabis"}]}],["$","li",null,{"className":"nav-item","children":["$","a",null,{"className":"nav-link","href":"/newsletters","children":"Press Releases"}]}],["$","li",null,{"className":"nav-item","children":["$","a",null,{"className":"nav-link","href":"/news","children":"News"}]}],["$","li",null,{"className":"nav-item","children":["$","a",null,{"className":"nav-link","href":"/companies/psychedelics","children":"Psychedelics"}]}]]}]]}]}]}]}],["$","div",null,{"className":"my-2 w-100 text-center bg-white"}],["$","section",null,{"id":"app","children":["$","div",null,{"className":"container","children":["$","article",null,{"className":"news","children":[["$","h1",null,{"children":"J&J misses revenue estimates as blockbuster drugs disappoint"}],["$","div",null,{"className":"row","children":[["$","div",null,{"className":"col-lg-5","children":["$","div",null,{"className":"image-holder","children":["$","img",null,{"src":"//s4.reutersmedia.net/resources/r/?m=02&d=20200122&t=2&i=1479763531&r=LYNXMPEG0L12Z&w=2000","className":"lazy","alt":"J&J misses revenue estimates as blockbuster drugs disappoint"}]}]}],["$","div",null,{"className":"col-lg-7","children":["$","p",null,{"dangerouslySetInnerHTML":{"__html":"Johnson & Johnson narrowly missed quarterly revenue estimates on Wednesday as sales of its blockbuster psoriasis medicine Stelara and cancer drug Imbruvica fell short of expectations.

$\"\"/$ "}}]}]]}]]}]}]}],["$","footer",null,{"children":["$","div",null,{"className":"container","children":["$","div",null,{"className":"row","children":[["$","div",null,{"className":"col-md-6 copyright","children":["© Private Equity Markets ",2026," | All Rights Reserved"]}],["$","div",null,{"className":"col-md-6 text-right","children":[["$","a",null,{"href":"/disclaimer","style":{"color":"white"},"children":"Disclaimer"}],["$","a",null,{"href":"/contact","className":"pl-2 pr-2","style":{"color":"white"},"children":"Contact Us"}]]}]]}]}]}]]